Paulus Stoffels - Johnson Johnson Chairman

JNJB34 Stock  BRL 52.55  0.95  1.84%   

Chairman

Dr. Paulus A. Stoffels is the Vice Chairman Executive Committee, Chief Scientific Officer of the Company. Dr. Stoffels joined the Company in 2002 with the acquisition of Tibotec Virco NV, where he was Chief Executive Officer of Virco NV and Chairman of Tibotec NV. In 2005, he was appointed Company Group Chairman, Global Virology. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the Central Nervous System and Internal Medicine Franchises since 2018.
Age 56
Tenure 6 years
Professional MarksPh.D
Phone732 524 0400
Webhttps://www.jnj.com
Stoffels was appointed Global Head, Research & Development, Pharmaceuticals in 2009, and in 2011, became Worldwide Chairman, Pharmaceuticals, with responsibility for the Company therapeutic pipeline through global research and development and strategic business development. In 2012, Dr. Stoffels was appointed Chief Scientific Officer, with responsibility for enterprisewide innovation and product safety, and became a member of the Executive Committee. In April 2016, Dr. Stoffels was named Executive Vice President, Chief Scientific Officer. He is responsible for the Company’s innovation pipeline across the pharmaceutical, medical devices and consumer segments and steers the Company’s global public health strategy.

Johnson Johnson Management Efficiency

The company has return on total asset (ROA) of 0.0881 % which means that it generated a profit of $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2414 %, meaning that it generated $0.2414 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 29.98 B in total debt with debt to equity ratio (D/E) of 51.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Johnson Johnson has a current ratio of 1.41, which is within standard range for the sector. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

CHAIRMAN Age

Jorge BittarTelecomunicaes Brasileiras SA
N/A
Peter GrunowMAHLE Metal Leve
66
Andre BorgesTelecomunicaes Brasileiras SA
55
Maximiliano MartinhaoTelecomunicaes Brasileiras SA
46
Craig MenearThe Home Depot
59
Lowell McAdamVerizon Communications
62
Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. JOHNSON DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 135100 people. Johnson Johnson (JNJB34) is traded on Sao Paulo Exchange in Brazil and employs 35 people.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dirk Brinckman, Chief Officer
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Ex CFO
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Robert Decker, Controller Officer
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
James Swanson, Ex Officer
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Vice President - Investor Relations
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Jessica Moore, VP Relations
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Elizabeth Forminard, Exec Counsel
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Vice President - Global Human Resources
Susan Lindquist, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Johnson Stock refer to our How to Trade Johnson Stock guide.
Note that the Johnson Johnson information on this page should be used as a complementary analysis to other Johnson Johnson's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
CEOs Directory
Screen CEOs from public companies around the world
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.